BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Exosomes » Page 16

Current and Future Opportunities for Stem Cell Exosomes

January 11, 2018 By Cade Hildreth (CEO) Leave a Comment

To operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. Currently, there are five market segments that compose the market for stem cell exosomes. These market segments include: Exosome therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. [Read more…]

Filed Under: Exosomes Tagged With: exosomes

BioInformant Releases “Market for Stem Cell Exosomes”

December 27, 2017 By Cade Hildreth (CEO) Leave a Comment

Exosome Market - Domain Names

Washington DC (Newswire) — BioInformant has launched the “Market for Stem Cell Exosomes – Products, Services, & Technologies,” a global strategic report targeting the growing demand for exosome therapeutics, diagnostics, and research tools.

Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes will play a crucial role in the cell therapy movement.

Exosome Market - Domain NamesBased in Washington, DC, BioInformant is the first and only market research firm to specialize in the stem cell industry. With more than a decade of experience in tracking the stem cell industry (2006 to present), BioInformant has a robust database on which to base future market predictions. Written for companies developing exosome-related products and technologies, the report analyzes strategic opportunities for commercializing products involving exosomes derived from stem cells, as well as other cell sources. [Read more…]

Filed Under: Exosomes Tagged With: capricor therapeutics, Codiak Biosciences, ExCoBio, exosomes, Kimera Labs, Lonza

Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery

December 20, 2017 By Cade Hildreth (CEO) Leave a Comment

Evox Therapeutics and Boehringer Ingelheim

Adds to list of pharmaceutical partners collaborating with Evox

OXFORD, England, December 19, 2017–Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has entered into a research collaboration with Boehringer Ingelheim to investigate exosome-mediated delivery of RNAs with high medical relevance to targets for specific disease areas of focus to Boehringer Ingelheim. The collaboration is part of Boehringer Ingelheim’s Research Beyond Borders (RBB) initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.
[Read more…]

Filed Under: Exosomes Tagged With: Boehringer Ingelheim, Evox Therapeutics

Exosome Diagnostics May Predict Which Cancers are Invasive (and Which are “Safe”)

December 12, 2017 By Cade Hildreth (CEO) Leave a Comment

Exosome diagnostics cancer

During the fall months of cancer campaigning, perhaps the biggest awareness remains in shadow: it is not yet possible to prevent patients from receiving needless treatment. As it stands, conservative estimates have determined that greater than 50% of men and women undergo unnecessary surgery and chemotherapy[1]. Many cancers do not deserve the dreaded name and are beginning to be labeled as non-progressive or indolent (“IDLEs”)[2] –a categorization that by itself may prevent untold psychological and physical trauma.

Exosome Diagnostics May Predict Invasiveness

Savvy researchers recognize that the most accurate information providing that distinction will come from what cells release into the blood like molecular mail[3]. Cancer or IDLEs, regardless of threat level, release clues regarding structural rearrangements, as well as tell-tail enzymes that allow cell migration, commandeer local metabolism, and resist their pollution. Profiling these clues would enable scientists and doctors to determine the necessity and precision of therapy, rather than automatically prescribing aggressive treatment.

Studying Exosomes Can Identify Cancer Severity

Cancer Exosome QuantitiesSuch mail is not released “naked” but in little parcels of cell membrane called extracellular vesicles (EVs) or exosomes. Exosomes are produced by all cells in day to day bodily functions, but on a cell-for-cell basis, cancers release larger quantities of exosomes[4].   [Read more…]

Filed Under: Exosomes

Opening Cancer’s Mail: Cancer Exosomes Contain “Inventory of Intent”

December 10, 2017 By Cade Hildreth (CEO) Leave a Comment

Breast Cancer Society of CanadaCurrently over 50% of men and women are directed to unnecessary treatment or surgery.  A new approach may help. Professor Alan Doucette of Dalhousie University and his colleagues have published a study funded by the Breast Cancer Society of Canada in which they capture particles released by rapidly growing cells called exosomes. Like parcels containing tools and instructions, exosomes contain an “inventory of intent.” Meaning, the cells that have released them contain genetic material proteins and metabolites that promote invasion of normal cells and commandeer their resources. [Read more…]

Filed Under: Exosomes, Stem Cell News Tagged With: cancer, exosomes

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.